BRIEF published on 11/04/2024 at 20:10, 16 days 14 hours ago Evolution of the number of shares and voting rights of Poxel in 2024 Share Capital Voting Rights Actions AMF Biopharmaceutical
BRIEF published on 10/11/2024 at 07:35, 1 month 10 days ago Poxel Releases 2023 Universal Registration Document Corporate Governance Annual Financial Report CSR Report Poxel 2023 Registration Document
PRESS RELEASE published on 10/11/2024 at 07:30, 1 month 10 days ago Annual financial and audit reports / Terms of availability of the annual financial report Poxel announces availability of the 2023 Universal Registration Document including financial and governance reports, now filed with the AMF AMF Biopharmaceutical Company Financial Report Universal Registration Document Poxel
BRIEF published on 10/03/2024 at 18:35, 1 month 17 days ago Poxel announces its financial and strategic results for 2023 Financial Results Biopharmaceutical TWYMEEG® Poxel OrbiMed
BRIEF published on 09/30/2024 at 07:35, 1 month 21 days ago Poxel Secures $50M Non-Dilutive Financing from OrbiMed Non-dilutive Financing TWYMEEG® Poxel Royalty Monetization OrbiMed
PRESS RELEASE published on 09/30/2024 at 07:30, 1 month 21 days ago Inside Information / Other news releases Poxel monetizes TWYMEEG® royalties in a USD 50 million deal with OrbiMed. Proceeds to reduce debt and support rare disease activities. Webinars scheduled for investor updates Webinars Royalties TWYMEEG® Poxel OrbiMed
BRIEF published on 09/09/2024 at 07:35, 2 months 12 days ago POXEL announces a significant increase in its sales in the second quarter of 2024 Sales Treasury Partnerships TWYMEEG® Poxel
BRIEF published on 08/16/2024 at 08:16, 3 months 5 days ago Poxel: Evolution of the Share Capital and the Number of Voting Rights Share Capital Voting Rights Actions AMF Poxel
BRIEF published on 08/07/2024 at 08:05, 3 months 14 days ago Sumitomo Pharma and Poxel Unveil Study Results of TWYMEEG® for Type 2 Diabetes TWYMEEG® Poxel Sumitomo Pharma Type 2 Diabetes Renal Failure
PRESS RELEASE published on 08/07/2024 at 08:00, 3 months 14 days ago Inside Information / Other news releases Sumitomo Pharma and Poxel announce topline results from post-marketing clinical study on TWYMEEG(R) for Type 2 Diabetes treatment in Japan. Safety, tolerability confirmed in renal impairment patients Japan Poxel Sumitomo Pharma Type 2 Diabetes TWYMEEG
Published on 11/21/2024 at 10:03, 36 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 39 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 39 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 4 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 14 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:04, 34 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 37 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 39 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 39 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 38 minutes ago Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 06:58, 3 hours 41 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 19 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 54 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 54 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
